BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2 clinical study of NurOwn® in amyotrophic lateral sclerosis (ALS) at the Inaugural "Cell & Gene Exchange" conference in Washington DC. Dr. Ralph Kern, MD, Chief Operating Officer & Chief Medical Officer, will participate in a panel titled "Clinical updates: Promising cell and gene therapy programs," followed by a company update delivered by Chaim Lebovits, Chief Executive Officer.
| Cell & Gene Exchange |
|
| Date: |
Tuesday, May 23 |
| Time: |
9:00am EDT |
| Location: |
Ronald Reagan Building, Washington DC |
| Title: |
Clinical updates: Promising cell and gene therapy programs |
| Presenter: |
Dr. Ralph Kern, MD, Chief Operating Officer & Chief Medical Officer |
| Date: |
Tuesday, May 23 |
| Time: |
3:15pm EDT |
| Location: |
Ronald Reagan Building, Washington DC |
| Title: |
Industry Presentations |
| Presenter: |
Chaim Lebovits, Chief Executive Officer |
About the Cell & Gene Exchange
The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. The goal is facilitating conversations among patient groups and key stakeholders to advancing potentially curative therapies for life-threatening diseases. More information about the Cell & Gene Exchange can be found here: https://ebdgroup.knect365.com/cellgene-exchange/
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult mesenchymal stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
CONTACTS
Media:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
[email protected]
Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
[email protected]
SOURCE BrainStorm Cell Therapeutics Inc.
Share this article